Share information

The price of the Novozymes B share ended the year at DKK 486, up DKK 141 or 41% from the beginning of the year.

The Novozymes share performed 29 percentage points better than the Copenhagen Stock Exchange’s OMXC20 blue-chip index, which climbed 12% during the year. Relative to other relevant stock indices the trend was also for the Novozymes share to gain more than the average.

In 2006, for the sixth year in a row, Dow Jones Sustainability Indexes named Novozymes as the listed biotechnology company with the greatest capacity, both in Europe and worldwide, to generate long-term shareholder value by exploiting opportunities and managing risks deriving from economic, environmental and social factors.

Novozymes’ market capitalisation at the end of the year was DKK 31.6 billion. In terms of trading, the share was the 11th most traded on the Copenhagen Stock Exchange. Share turnover was fairly stable during the year. On an average day 225,000 shares were traded.

At Novozymes A/S’ Annual Meeting of Shareholders on March 1, 2006 a decision was taken to write down the share capital by 4.6 million B shares, corresponding to DKK 46 million. Following this write-down, the share capital is DKK 650 million, corresponding to 65.0 million shares.

Novozymes invested a total of DKK 1,107 million in share buy-backs in 2006, and holdings of treasury shares made up 4.9% of the total share capital at year-end.